So...how does this relate or help RVX?...

At some point soon, I want to cash out out on Zenith and severely underperforming Resverlogix.

Two potential candidates obviously are Pfizer and Hepalink. So, plain and simple, I watch their moves.

Pfizer's CEO made some remarks back in late January that struck a chord with many Resverlogix shareholders at that time, as they appeared to be tailor-made for a RVX-Zenith takeout. You can go back and read them. However, it would be foolish to dismiss Hepalink's smaller footprint, and so we will finally see (and soon I hope) if this Hong Kong listing has anything to do with their broader ambitions.

Any bets out there who got the "China data" first?